Professor Francois Venter and Dr Simiso Sokhela write in a Spotlight report: “South Africa’s next big shift in our antiretroviral programme is to replace Efavirenz...Weekly Roundup
The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical...Medico-Legal
Pharmaceuticals company Gilead is set to lose intellectual property rights for a drug it developed to treat HIV, freeing other drugs companies to launch generic...
June 13th, 2018The newer high-sensitivity troponin test discovers smaller amounts of heart-specific proteins, troponins, than the older troponin test and thus identifies more...
An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical...Weekly Roundup
A leading Aids researcher and proponent of medication-assisted therapy for addiction has been appointed to oversee the US Centres for Disease Control and Prevention,...Weekly Roundup
This has been a lively year for HIV research says an i-base report. Even though only one new drug was approved (a once-daily version of raltegravir) several key generic...Pharmacology
For a rich country that is a global hub for pharma companies, Switzerland is going to extraordinary lengths to avoid hepatitis C patients having to pay for pricey...HIV/AIDS
Patients with HIV experienced a significantly higher rate of virologic suppression after taking Gilead’s Genvoya (elivitegravir-cobicistat-emtricitabine-tenofovir...Infectious Diseases
France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide...
